The full U.S. Court of Appeals for the District of Columbia Circuit Oct. 16 denied AHA’s request to reconsider two decisions from this summer that upheld the Centers for Medicare & Medicaid Services’ cuts to payments for 340B drugs and for off-campus hospital outpatient clinic visits.

The full U.S. Court of Appeals declined to reconsider a July 31 decision by a three-judge panel that upheld the authority of CMS to lower by nearly 30% 2018 and 2019 Medicare outpatient prospective payment system drug payments for certain hospitals participating in the 340B Drug Pricing Program.

A district court had previously ruled in AHA’s favor, finding that the payment reductions were invalid. In addition, the court said it will not rehear a July 17 decision by a three-judge panel that upheld the authority of the Department of Health and Human Services to reduce payments for hospital outpatient services furnished in off-campus provider-based departments grandfathered under the Bipartisan Budget Act of 2015. A lower court twice found that HHS exceeded its statutory authority when it reduced these payments.

The AHA said it is deeply disappointed in the court’s decisions in both of these cases, which conflict with Congress’ clear intent and defer to the government’s inaccurate interpretation of the law. The association is evaluating all of its options to repeal these unlawful cuts, including petitioning the Supreme Court to hear the cases.

Related News Articles

Headline
The AHA today submitted comments on the Centers for Medicare & Medicaid Services’ outpatient prospective payment system and ambulatory surgical center…
Headline
The Department of Health and Human Services this week in a strongly worded letter to Eli Lilly calls into question recent actions by the drug manufacturer to…
Headline
The AHA again expressed concern to the Department of Health and Human Services about recent actions taken by several major drug manufacturers to limit the…
Headline
The AHA and other national health care groups yesterday urged the Department of Health and Human Services to protect 340B hospitals and the vulnerable…
Headline
The AHA today sent letters to the heads of U.S. operations for five large drug companies — Merck, Eli Lilly, Sanofi, Novartis and AstraZeneca — expressing “…
Headline
The U.S. Court of Appeals for the District of Columbia Circuit today overturned a 2018 district court decision that found the Department of Health and Human…